MDM2 and neoplasm: This study aimed to elucidate whether p53 reactivation by peptide 3 inhibitor of the MDM2/MDM4 heterodimer (14) formation, whose administration is known to inhibit tumor growth, could have beneficial effects on tumor progression by restoring antitumoral immune responses whilst avoiding the development of autoimmune responses.